2 weeks Ago By ABMN Staff
Bokf Na lessened its position in Sanofi ( NASDAQ:SNY – Free Report ) by 16.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,529 shares of the company’s stock after selling 502 shares during the period.
Bokf Na’s holdings in Sanofi were worth $123,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. POM Investment Strategies LLC bought a new position in Sanofi during the second quarter valued at approximately $25,000.
Frazier Financial Advisors LLC bought a new position in Sanofi during the fourth quarter valued at approximately $28,000. Register Financial Advisors LLC bought a new position in Sanofi during the first quarter valued at approximately $29,000. Larson Financial Group LLC lifted its position in Sanofi by 480.
8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares during the period. Finally, Johnson Financial Group Inc.
bought a new position in Sanofi during the fourth quarter valued at approximately $31,000. Institutional investors own 10.04% of the company’s stock.
Sanofi Stock Down 0.7 % Shares of SNY stock opened at $56.91 on Wednesday.
Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97.
The stock has a market cap of $144.14 billion, a P/E ratio of 28.60, a P/E/G ratio of 1.
60 and a beta of 0.60. The company has a current ratio of 1.
00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.
The company has a 50 day simple moving average of $53.95 and a two-hundred day simple moving average of $50.30.
Analysts Set New Price Targets A number of research analysts recently weighed in on SNY shares. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th.
Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th.
Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $57.
50. Read Our Latest Research Report on Sanofi About Sanofi ( Free Report ) Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments.
The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. Featured Articles Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi ( NASDAQ:SNY – Free Report ).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter ..
